On March 12, 2018 Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, reported an oral presentation and two poster presentations relating to the company’s drug development candidates (Press release, Crinetics Pharmaceuticals, MAR 12, 2018, View Source [SID1234525096]). These presentations will be made at the upcoming ENDO 2018, the Annual Meeting of the Endocrine Society, taking place from March 17-20, 2018 in McCormick Place West, Chicago, Illinois.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oral Presentation:

Title: Phase 1 Clinical Trial of CRN00808, an Orally Bioavailable sst2-Selective, Nonpeptide Somatostatin Biased Agonist for the Treatment of Acromegaly: Safety, Pharmacokinetics, and Inhibition of GHRH-Induced GH Secretion.
Session: OR06 – Pituitary Tumors: Acromegaly and Prolactinomas.
Poster: ORO6-3.
Date and Time: Saturday, March 17, 12-12:15 p.m. CDT
Location: W192.

Poster Presentations:

Title: Suppression of Growth Hormone and Insulin-Like Growth Factor 1 in Rats After Oral Administration of CRN00808, a Small Molecule, SST2 Selective Somatostatin Biased Agonist.
Session: P32 – Pituitary Transcription Factors and New Hormonal Signaling Pathways.
Poster: SUN-604.
Date and Time: Sunday, March 18, 1-3 p.m. CDT
Location: ENDOExpo, Hall F.

Title: Somatostatin Subtype 5 (sst5) Agonists for the Treatment of Hyperinsulinism: Orally-Bioavailable Small Molecules Suppress Insulin and Rescue Glyburide-Induced Hypoglycemia.
Session: P14-3 – Pediatric Endocrinology – Disorders of Sexual Differentiation, Transgender Medicine, Metabolic Disorders, and Growth.
Poster: MON-193.
Date and Time: Monday, March 19, 1-3 p.m. CDT
Location: ENDOExpo, Hall F.

Akebia has filed a 10-K – Annual report [Section 13 and 15(d), not S-K Item 405] with the U.S. Securities and Exchange Commission (Filing, 10-K, Akebia, 2018, MAR 12, 2018, View Source [SID1234524657]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On March 12, 2018 Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, reported that it will hold a conference call on Wednesday, March 14, 2018 at 1:30 PM Pacific Time (4:30 PM Eastern Time) to discuss fourth quarter 2017 year-end financial results and provide a corporate update (Press release, Arbutus Biopharma, MAR 12, 2018, View Source [SID1234524668]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the conference call, a live webcast of the call can be accessed through the Investor section of Arbutus’ website at www.arbutusbio.com. Or, alternatively, to access the conference call, please dial 1-914-495-8556 or 1-866-393-1607.

An archived webcast will be available on the Arbutus website after the event. Alternatively, you may access a replay of the conference call by calling 1-404-537-3406 or 1-855-859-2056 and referencing conference ID 8777644.

On March 12, 2018 -Illumina, Inc. (NASDAQ:ILMN) reported the appointment of Dr. Phil Febbo, a leading physician scientist, as Chief Medical Officer (CMO), starting March 26, 2018 (Press release, , DEC 12, 2018, View Source [SID1234524691]). In his new role, Dr. Febbo will be responsible for developing and executing on the Company’s medical strategy to drive genomic testing into healthcare practice.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are very excited to welcome Dr. Febbo, who comes to us at a transformative time in the evolution of genomic medicine"

Tweet this
"We are very excited to welcome Dr. Febbo, who comes to us at a transformative time in the evolution of genomic medicine," said Garret Hampton, Ph.D., Executive Vice President of Clinical Genomics at Illumina. "Phil brings a wealth of clinical and scientific experience to Illumina, from understanding the genomic basis of common human cancers, to the development of clinical tests based on next generation sequencing. We believe that his experience will ensure that Illumina is uniquely positioned to change medical practice with the use of genomics."

For the past 25 years, Dr. Febbo has worked at leading institutions throughout the United States, most recently serving as CMO of Genomic Health (NASDAQ:GHDX). Prior to joining Genomic Health, Dr. Febbo served as Professor of Medicine and Urology at the University of California, San Francisco (UCSF), where his laboratory focused on using genomics to understand the biology and clinical behavior of prostate cancer, and his clinical practice focused on genitourinary oncology. While at UCSF, Dr. Febbo was the co-leader of the Prostate Cancer Program at the Helen Diller Family Comprehensive Cancer Center and the Program Principal Investigator of the Translational Research Program for the Alliance for Clinical Trials in Oncology.

Dr. Febbo holds a Bachelor of Arts degree in Biology from Dartmouth College, received his M.D. degree at UCSF, and completed his internal medicine residency at the Brigham and Women’s Hospital. After his fellowship in medical oncology at the Dana-Farber Cancer Institute, he was an Attending Physician in the Genitourinary Oncology Center at Dana-Farber, Instructor at Harvard Medical School, and a post-doctoral fellow in Dr. Todd Golub’s laboratory at Dana-Farber, as well as the Whitehead Institute Center for Genomic Research of MIT (now the Broad Institute). In 2004, Dr. Febbo moved to Duke University Medical Center’s Institute of Genome Sciences and Policy. He has been a member of the American Society for Clinical Investigation since 2009.

NantKwest has filed a 10-K – Annual report [Section 13 and 15(d), not S-K Item 405] with the U.S. Securities and Exchange Commission (Filing, 10-K, NantKwest, 2018, MAR 12, 2018, View Source [SID1234524658]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!